Hydroxychloroquine Dosing Guidelines

Introduction to Hydroxychloroquine Dosing

The standard adult dosing for malaria treatment requires 600 mg base initially, followed by 300 mg base at 6, 24, and 48 hours, for a total of 1500 mg base over 3 days, as recommended by the Centers for Disease Control and Prevention 1, 2, 3
Pediatric dosing is 10 mg base/kg initially (maximum 600 mg base), according to the American Academy of Pediatrics 1
A dose of 235 mg falls far short of the initial therapeutic requirement and would be inadequate for treating active malaria, as stated by the World Health Organization 1

Weekly prophylaxis uses 300 mg base (500 mg salt) once weekly for chloroquine-sensitive areas, as recommended by the Centers for Disease Control and Prevention 4
For chloroquine-resistant areas, alternative regimens are recommended by the World Health Organization 4
A 235 mg dose does not match the weekly prophylactic standard, according to the Centers for Disease Control and Prevention 4

Dosing should not exceed 5 mg/kg of actual body weight per day to minimize retinopathy risk, as recommended by the American College of Rheumatology 3
For a 70 kg patient, this translates to approximately 350 mg daily maximum, according to the European League Against Rheumatism 3

The appropriateness of any hydroxychloroquine dose depends entirely on the patient's actual body weight, indication for use, and duration of intended therapy, as stated by the National Institutes of Health 1, 4
The indication for use, such as malaria treatment, prophylaxis, or rheumatologic disease, has completely different dosing paradigms, according to the Centers for Disease Control and Prevention 1, 4

Avoid underdosing for acute malaria, as inadequate initial dosing leads to treatment failure and requires alternative therapy, as recommended by the World Health Organization 2, 3
Do not confuse salt and base formulations, as hydroxychloroquine sulfate 200 mg tablets contain 155 mg base, while chloroquine phosphate 500 mg contains 300 mg base, according to the Food and Drug Administration 1